GOSSGossamer Bio, Inc.

Nasdaq gossamerbio.com


$ 0.52 $ -0.03 (-5.52 %)    

Monday, 10-Jun-2024 10:29:19 EDT
QQQ $ 463.08 $ 0.29 (0.06 %)
DIA $ 388.28 $ -0.21 (-0.05 %)
SPY $ 533.58 $ 0.33 (0.06 %)
TLT $ 91.00 $ -0.03 (-0.03 %)
GLD $ 213.10 $ 0.01 (0 %)
$ 0.5484
$ 0.55
$ 0.00 x 0
$ 0.52 x 300
$ 0.51 - $ 0.55
$ 0.45 - $ 1.88
1,100,710
na
123.79M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

 gossamer-bio-provides-updated-seralutinib-torrey-open-label-extension-data-at-the-american-thoracic-society-2024-international-conference-which-takes-place-may-17-22

Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization o...

 wedbush-reiterates-outperform-on-gossamer-bio-maintains-4-price-target

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

 gossamer-bio-q1-eps-019-misses-018-estimate

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18...

 gossamer-bio-collaborates-with-italian-drugmaker-chiesi-to-advance-lung-health-solutions-worldwide

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hyperte...

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

 gossamer-bio-secures-160m-partnership-with-chiesi-group-to-accelerate-development-of-pulmonary-hypertension-treatment-486m-potential-for-seralutinib-collaboration

Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development an...

 wedbush-assumes-gossamer-bio-at-outperform-announces-price-target-of-4

Wedbush analyst Laura Chico assumes Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $4.

 piper-sandler-maintains-overweight-on-gossamer-bio-maintains-15-price-target

Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and maintains $15 price target.

 goldman-sachs-maintains-buy-on-gossamer-bio-lowers-price-target-to-8

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $9 to $8.

 wedbush-reiterates-outperform-on-gossamer-bio-maintains-6-price-target

Wedbush analyst Andreas Argyrides reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $6 price target.

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION